Cargando…

Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study)　― Protocol of a Multicenter Randomized Control Trial ―

Background: The latest guideline from the European Society of Cardiology and European Respiratory Society recommends initial combination therapy with oral pulmonary arterial hypertension (PAH)-specific drugs in PAH patients with World Health Organization functional class (WHO-FC) II or III. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akagi, Satoshi, Dohi, Yoshihiro, Ishikawa, Kaori, Kubota, Kayoko, Horimoto, Koshin, Yagi, Shusuke, Hirata, Tetsuo, Yamamoto, Eiichiro, Ito, Hiroshi, Nakamura, Kazufumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Circulation Society 2021
Materias:	Protocol Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939949/ https://www.ncbi.nlm.nih.gov/pubmed/33693297 http://dx.doi.org/10.1253/circrep.CR-20-0133

Ejemplares similares

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
por: Sulica, Roxana, et al.
Publicado: (2019)

Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report
por: Lattanzio, Mariangela, et al.
Publicado: (2022)

Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects
por: Csonka, Dénes, et al.
Publicado: (2019)

Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

Macitentan in the treatment of pulmonary hypertension in Gaucher’s disease
por: Taylan, Gökay, et al.
Publicado: (2020)

The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities
por: Saad, Nancy S., et al.
Publicado: (2016)

Macitentan: An important addition to the treatment of pulmonary arterial hypertension
por: Khadka, Anjan, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

The use of Macitentan in Fontan circulation: a case report
por: Demetriades, Polyvios, et al.
Publicado: (2017)

Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension
por: Kim, Kyung-Hee, et al.
Publicado: (2018)

Swift and Complete Healing of Digital Ulcers after Macitentan Treatment
por: Giner Serret, Emilio
Publicado: (2016)

Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension
por: Jung, Hae Ok
Publicado: (2018)

Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
por: Wong, Alexandra K, et al.
Publicado: (2019)

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

The Endothelin Receptor Antagonist Macitentan Inhibits Human Cytomegalovirus Infection
por: Landázuri, Natalia, et al.
Publicado: (2021)

Effects of bergapten on the pharmacokinetics of macitentan in rats both in vitro and in vivo
por: Xu, Jia, et al.
Publicado: (2023)

Efficacy and safety of macitentan for pulmonary hypertension: A meta‐analysis
por: Du, Dan, et al.
Publicado: (2023)

Macitentan: entry-into-humans study with a new endothelin receptor antagonist
por: Sidharta, Patricia N., et al.
Publicado: (2011)

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
por: Monaco, Thomas J, et al.
Publicado: (2016)

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
por: Nosrati, Marzieh, et al.
Publicado: (2020)

Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series
por: Mathijssen, H., et al.
Publicado: (2020)

Macitentan attenuates cardiovascular remodelling in infant rats with chronic lung disease
por: Baumann, Philipp, et al.
Publicado: (2022)

Macitentan for the Treatment of Refractory Digital Ulcers in Patients With Connective Tissue Diseases
por: Soto Abánades, Clara, et al.
Publicado: (2023)

Review of Setouchi International Art Festival/Setouchi Triennale 2016
por: Tanaka, Kathryn M.
Publicado: (2016)

Macitentan treatment retards the progression of established pulmonary arterial hypertension in an animal model()
por: Temple, I.P., et al.
Publicado: (2014)

Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial
por: Jansa, Pavel, et al.
Publicado: (2017)

Distinct ET(A) Receptor Binding Mode of Macitentan As Determined by Site Directed Mutagenesis
por: Gatfield, John, et al.
Publicado: (2014)

Evaluation of Macitentan in Patients With Eisenmenger Syndrome: Results From the Randomized, Controlled MAESTRO Study
por: Gatzoulis, Michael A., et al.
Publicado: (2019)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Less Vertebral Bone Mass after Treatment with Macitentan in Mice: A Pilot Study
por: Liu, Zhong-Yu, et al.
Publicado: (2019)

The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up
por: Jariwala, Pankaj, et al.
Publicado: (2022)

Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review
por: Li, Niuniu, et al.
Publicado: (2023)

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
por: Bruderer, Shirin, et al.
Publicado: (2011)

Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study
por: Corallo, Claudio, et al.
Publicado: (2016)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
por: Mamazhakypov, Argen, et al.
Publicado: (2020)

Bioequivalence of macitentan and tadalafil given as fixed‐dose combination or single‐component tablets in healthy subjects
por: Grill, Simon, et al.
Publicado: (2020)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ckljki64o8q2t3mm1d7oer40h